Volume 152, Issue 1, Pages (January 2019)

Slides:

Advertisements

Similar presentations

1 Copyright © 2010, Elsevier Inc. All rights Reserved Fig 4.1 Chapter 4.

Advertisements

What We Talk About When We Talk About Fat Evan D. Rosen, Bruce M. Spiegelman Cell Volume 156, Issue 1, Pages (January 2014) DOI: /j.cell

Origins of Metastatic Traits Sakari Vanharanta, Joan Massagué Cancer Cell Volume 24, Issue 4, Pages (October 2013) DOI: /j.ccr

Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem

Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia Tim C.P. Somervaille, Michael L. Cleary Cancer Cell.

The Microbiome and Cancer: Is the ‘Oncobiome’ Mirage Real? Ryan M. Thomas, Christian Jobin Trends in Cancer Volume 1, Issue 1, Pages (September 2015)

ABO-incompatible kidney transplantation Kota Takahashi, Kazuhide Saito Transplantation Reviews Volume 27, Issue 1, Pages 1-8 (January 2013) DOI: /j.trre

Adaptation to Natural Binocular Disparities in Primate V1 Explained by a Generalized Energy Model Ralf M. Haefner, Bruce G. Cumming Neuron Volume 57, Issue.

Port site metastasis after robotic-assisted laparoscopic hysterectomy for uterine cervical cancer: A case report and literature review BoKyong Kim, Seung.

Metastatic melanoma treatment: Combining old and new therapies Ryan J. Davey, Andre van der Westhuizen, Nikola A. Bowden Critical Reviews in Oncology /

Volume 144, Issue 1, Pages (January 2017)

A New Model for Imaging and Radiation Therapy Quality Assurance in the National Clinical Trials Network of the National Cancer Institute Thomas J. FitzGerald,

Volume 64, Pages e1-e3 (January 2017)

S.E. Knapen, M. van de Werken, M.C.M. Gordijn, Y. Meesters

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 146, Issue 2, Pages (August 2017)

Volume 148, Issue 1, Pages (January 2018)

Volume 148, Issue 1, Pages (January 2018)

Triantafyllos Stylianopoulos, Lance L. Munn, Rakesh K. Jain

Rajmohan Murali, Rachel N. Grisham, Robert A. Soslow

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

Volume 148, Issue 1, Pages (January 2018)

DAISY: Picking Synthetic Lethals from Cancer Genomes

Volume 145, Issue 2, Pages (May 2017)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

Volume 147, Issue 1, Pages 3-10 (October 2017)

The efficacy of mTORC1/2 inhibition on ovarian cancer stem cells

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Do Nurse Practitioners Need So Many Credentials?

Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum E.E. Stevens, J.N. Bottsford-Miller,

Volume 142, Issue 3, Pages (September 2016)

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Volume 152, Issue 1, (January 2013)

Volume 152, Issue 1, Pages (January 2019)

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Volume 143, Issue 2, Pages (November 2016)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

The origins of multidisciplinary cancer care

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM) C. Popadiuk, A.J. Coldman,

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Volume 152, Issue 1, Pages (January 2019)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 1, Pages (October 2017)

Volume 152, Issue 1, Pages (January 2019)

Neuropsychological Assessment of Sport-Related Concussion

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough K.M. Doll, E.L. Barber, J.T. Bensen,

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 1, Pages (July 2013)

Volume 152, Issue 1, Pages (January 2019)

Treatment of Colorectal Cancer

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

In This Issue Journal of Thoracic Oncology

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 3, Pages (December 2017)

Volume 152, Issue 1, Pages (January 2019)

High-risk cancer, unequal care: Disparities in the complete surgical staging of high- grade endometrial cancer in the Southeastern United States J.R.

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Volume 115, Issue 1, Pages (October 2009)

Presentation transcript:

Volume 152, Issue 1, Pages 106-111 (January 2019) Disparities in the allocation of research funding to gynecologic cancers by Funding to Lethality scores Ryan J. Spencer, Laurel W. Rice, Clara Ye, Kaitlin Woo, Shitanshu Uppal Gynecologic Oncology Volume 152, Issue 1, Pages 106-111 (January 2019) DOI: 10.1016/j.ygyno.2018.10.021 Copyright © 2018 Elsevier Inc. Terms and Conditions

Fig. 1 Funding to Lethality trends 2007–2014. Scales are the same for all three graphs. Cancer sites divided for ease of identification and by 2014 score from highest to lowest. Gynecologic Oncology 2019 152, 106-111DOI: (10.1016/j.ygyno.2018.10.021) Copyright © 2018 Elsevier Inc. Terms and Conditions

Fig. 2 Eight-year mean Funding to Lethality scores 2007–2014. Score calculated by total amount of annual funding in U.S. dollars reported by the NCI divided by the person-years of life lost per 100 new cases. Gynecologic Oncology 2019 152, 106-111DOI: (10.1016/j.ygyno.2018.10.021) Copyright © 2018 Elsevier Inc. Terms and Conditions

Fig. 3 Funding to Lethality score trends for gynecologic cancers. Gynecologic Oncology 2019 152, 106-111DOI: (10.1016/j.ygyno.2018.10.021) Copyright © 2018 Elsevier Inc. Terms and Conditions